[Roferon: present and future indications].
Ostronoff
M
M
Institut Gustave-Roussy, Villejuif, France.
Zambon
E
E
Schlumberger
M
M
Parmentier
C
C
Hayat
M
M
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D006801:Humans; D007370:Interferon Type I / Q000627:therapeutic use; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D009369:Neoplasms / Q000188:drug therapy; D011994:Recombinant Proteins
D000970:Antineoplastic Agents; D007370:Interferon Type I; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins